Literature DB >> 10781781

Ursodeoxycholic acid therapy in hepatobiliary disease.

K V Kowdley1.   

Abstract

Ursodeoxycholic acid is a hydrophilic bile acid that under normal circumstances represents a small fraction of the bile acid pool in humans. It is effective in dissolving cholesterol gallstones in appropriately selected patients. Ursodeoxycholic acid improves serum alkaline phosphatase and aminotransferase levels in primary biliary cirrhosis, but its effects on rates of liver transplantation and death are less certain. Ursodeoxycholic acid has had promising [corrected] effects in several other cholestatic liver diseases, such as cystic fibrosis and intrahepatic cholestasis of pregnancy, but data are too preliminary to make recommendations about its routine use in these conditions. Its effects are mediated by amelioration of damage to cell membranes caused by retained toxic bile acids. Ursodeoxycholic acid improves biliary secretion of bile acids, may improve bile flow, and it has immunomodulatory properties that may reduce immune-mediated liver damage. However, its use in the treatment of cholestatic liver disease remains uncertain pending additional randomized trials.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10781781     DOI: 10.1016/s0002-9343(00)00318-1

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  16 in total

1.  Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF-κB activation in benign Barrett's epithelial cells.

Authors:  Xiaofang Huo; Stefanie Juergens; Xi Zhang; Davood Rezaei; Chunhua Yu; Eric D Strauch; Jian-Ying Wang; Edaire Cheng; Frank Meyer; David H Wang; Qiuyang Zhang; Stuart J Spechler; Rhonda F Souza
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-06-02       Impact factor: 4.052

2.  Specific bile acids inhibit hepatic fatty acid uptake in mice.

Authors:  Biao Nie; Hyo Min Park; Melissa Kazantzis; Min Lin; Amy Henkin; Stephanie Ng; Sujin Song; Yuli Chen; Heather Tran; Robin Lai; Chris Her; Jacquelyn J Maher; Barry M Forman; Andreas Stahl
Journal:  Hepatology       Date:  2012-10       Impact factor: 17.425

3.  In Barrett's esophagus patients and Barrett's cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids.

Authors:  Sui Peng; Xiaofang Huo; Davood Rezaei; Qiuyang Zhang; Xi Zhang; Chunhua Yu; Kiyotaka Asanuma; Edaire Cheng; Thai H Pham; David H Wang; Minhu Chen; Rhonda F Souza; Stuart Jon Spechler
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-05-22       Impact factor: 4.052

4.  The effect of ursodeoxycholic acid in liver functional restoration of patients with obstructive jaundice after endoscopic treatment: a prospective, randomized, and controlled study.

Authors:  Enver Fekaj; Arben Gjata; Mehmet Maxhuni
Journal:  BMC Surg       Date:  2013-09-22       Impact factor: 2.102

Review 5.  Pharmacology of bile acids and their derivatives: absorption promoters and therapeutic agents.

Authors:  M Mikov; J P Fawcett; K Kuhajda; S Kevresan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2006 Jul-Sep       Impact factor: 2.441

Review 6.  Biliary Strictures: Etiologies and Medical Management.

Authors:  Terrance Rodrigues; Justin R Boike
Journal:  Semin Intervent Radiol       Date:  2021-08-10       Impact factor: 1.780

7.  Effects of long term hydrophilic bile acid therapy on in vitro contraction of gallbladder muscle strips in patients with cholesterol gallstones.

Authors:  Mehmet-Refik Mas; Bilgin Comert; Nuket Mas; Levent Yamanel; Haluk Ozotuk; Ilker Tasci; Riadh-P Jazrawi
Journal:  World J Gastroenterol       Date:  2007-08-28       Impact factor: 5.742

8.  Combined endoscopic and ursodeoxycholic acid treatment of biliary cast syndrome in a non-transplant patient.

Authors:  Panagiotis Katsinelos; Jannis Kountouras; Grigoris Chatzimavroudis; Christos Zavos; Ioannis Pilpilidis; George Paroutoglou
Journal:  World J Gastroenterol       Date:  2008-09-07       Impact factor: 5.742

9.  Treatment of Nonalcoholic Fatty Liver Disease.

Authors:  Suthat Liangpunsakul; Naga Chalasani
Journal:  Curr Treat Options Gastroenterol       Date:  2003-12

10.  Treatment options for chronic cholestasis in infancy and childhood.

Authors:  Vicky Lee Ng; William F Balistreri
Journal:  Curr Treat Options Gastroenterol       Date:  2005-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.